Good News for Tysabri

There have been no additional reports of a serious brain infection known as progressive multifocal leukoencephalopathy, or PML, among patients taking the multiple-sclerosis drug Tysabri, the drug’s makers said Thursday.

Biogen Idec Inc. and Elan Corp., also said there were no reports of other “serious opportunistic infections,” as of April 23. The companies released the first safety update involving Tysabri since the drug was allowed back in the U.S. market last June. The data was released at the American Academy of Neurology’s annual meeting on Boston.

Click here for the whole article or google “New Tysabri Reports”


2 responses to “Good News for Tysabri

  1. Hi Courtney, I agree that was a good article, with one HUGE error by Ms. Dooreen (note: the full article is no longer available for free by the WSJ), but I have it listed in it’s entirety at the end of my 5/7/07 entry, along with my email to her and ALL her editors (heehee)

    Feel better soon dearheart.

    Lauren 🙂

  2. What is it that the editorialized version left out?

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s